Literature DB >> 11200074

Natural and synthetic agonists of the melanocortin receptor type 3 possess anti-inflammatory properties.

S J Getting1, G H Allcock, R Flower, M Perretti.   

Abstract

The effects of the natural and synthetic ligands for the melanocortin receptor type 3 (MC3-R) have been evaluated in a murine model of experimental gout. Systemic treatment of mice with gamma2-melanocyte-stimulating hormone (gamma2-MSH) and the synthetic agonist MTII inhibited accumulation of KC, interleukin-1 beta (IL-1beta), and PMN elicited by urate crystals in the peritoneal cavity. In vitro, macrophage (Mø) activation, determined as release of KC and IL-1beta, was inhibited by gamma2-MSH and MTII. The mixed MC3/4-R antagonist SHU9119 prevented the inhibitory actions of gamma2-MSH and MTII in vitro and in vivo, whereas the selective MC4-R antagonist HS024 was without effect. Western blotting also showed the presence of MC3-R protein on murine peritoneal Mø. Furthermore, agonism at the MC3-R evoked accumulation of cAMP within the Mø, which was inhibited by SHU9119. Thus, naturally occurring melanocortins, as well as the synthetic long-acting compound MTII, activate MC3-R on peritoneal Mø to inhibit the experimental inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11200074

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  20 in total

1.  Functional melanocortin-2 receptors are expressed by mouse aorta-derived mesenchymal progenitor cells.

Authors:  Jodi F Evans; Anne Fernando; Louis Ragolia
Journal:  Mol Cell Endocrinol       Date:  2012-01-27       Impact factor: 4.102

2.  Morph-specific genetic and environmental variation in innate and acquired immune response in a color polymorphic raptor.

Authors:  Laura Gangoso; Alexandre Roulin; Anne-Lyse Ducrest; Juan Manuel Grande; Jordi Figuerola
Journal:  Oecologia       Date:  2015-04-04       Impact factor: 3.225

Review 3.  Melanotropins as drugs for the treatment of obesity and other feeding disorders: potential and problems.

Authors:  Minying Cai; Joel Nyberg; Victor J Hruby
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

Review 4.  Control of myeloid cell trafficking in resolution.

Authors:  Lucy V Norling; Mauro Perretti
Journal:  J Innate Immun       Date:  2013-04-30       Impact factor: 7.349

Review 5.  Role of proopiomelanocortin-derived peptides and their receptors in the osteoarticular system: from basic to translational research.

Authors:  Markus Böhm; Susanne Grässel
Journal:  Endocr Rev       Date:  2012-06-26       Impact factor: 19.871

6.  Systemic and local ACTH produced during inflammatory states promotes osteochondrogenic mesenchymal cell differentiation contributing to the pathologic progression of calcified atherosclerosis.

Authors:  Jodi F Evans; Louis Ragolia
Journal:  Med Hypotheses       Date:  2012-09-29       Impact factor: 1.538

7.  The regulation of food intake by selective stimulation of the type 3 melanocortin receptor (MC3R).

Authors:  Daniel L Marks; Victor Hruby; Gregor Brookhart; Roger D Cone
Journal:  Peptides       Date:  2005-11-04       Impact factor: 3.750

8.  Multivariate heredity of melanin-based coloration, body mass and immunity.

Authors:  S-Y Kim; J A Fargallo; P Vergara; J Martínez-Padilla
Journal:  Heredity (Edinb)       Date:  2013-04-17       Impact factor: 3.821

9.  ACTH promotes chondrogenic nodule formation and induces transient elevations in intracellular calcium in rat bone marrow cell cultures via MC2-R signaling.

Authors:  Jodi F Evans; Sylvana Rodriguez; Louis Ragolia
Journal:  Cell Tissue Res       Date:  2013-01-29       Impact factor: 5.249

10.  Mapping of a novel susceptibility locus suggests a role for MC3R and CTSZ in human tuberculosis.

Authors:  Graham S Cooke; Sarah J Campbell; Steve Bennett; Christian Lienhardt; Keith P W J McAdam; Giorgio Sirugo; Oumou Sow; Per Gustafson; Frank Mwangulu; Paul van Helden; Paul Fine; Eileen G Hoal; Adrian V S Hill
Journal:  Am J Respir Crit Care Med       Date:  2008-04-17       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.